Despite positive early signs for its newly launched drugs Alyftrek and Journavx, Vertex’s first-quarter sales missed analyst estimates partly due to an unauthorized Trikafta generic eating away at sales in Russia. More: Vertex, with new launches gaining steam, boosts revenue
read moreIn the wake of the high-profile departure of Peter Marks, M.D., Ph.D., the FDA has a new leader for its Center for Biologics Evaluation and Research. More: FDA Commissioner Marty Makary taps Vinay Prasad to head up CBER Source: fierce
read moreThe “ConnectING with Carnie” campaign page, hosted within the official Ingrezza website, includes testimonials from people with TD about the ways their lives changed after speaking up about their symptoms. More: Neurocrine holds on to branded tardive dyskinesia push with
read more
New initiative aims to accelerate diagnosis and ease NHS pressures More: Chiesi partners with Wirral Primary Care to improve COPD detection Source: News
read more
Company seeks approval for new schedules to improve patient convenience More: Johnson & Johnson submits application for subcutaneous Rybrevant dosing Source: News
read moreBristol Myers Squibb plans to invest $40 billion across U.S. R&D, technology and manufacturing over the next five years, CEO Chris Boerner said in an op-ed published by Stat this week. More: 'Now is not the time to retreat': BMS
read more© 1994 - 2026 B.M. Pharmaceuticals